are those that are minimally manipulated and intended for homologous use. Conversely, products that involve more than minimal manipulation or are intended for non-homologous use fall under a 351 application, requiring a more stringent regulatory pathway.

In Europe, the European Medicines Agency (EMA) defines ATMPs as therapies based on genes, tissues, or cells. Understanding the definitions provided in the EMA guidelines is critical for US sponsors as it helps delineate which regulatory pathway their product should follow, thereby informing their risk register.

Thus, a complete understanding of these classifications lays the groundwork for informed decision-making as sponsors assess their product’s regulatory pathway.

Step 2: Conducting Initial Product Classification Assessment

Upon establishing a clear understanding of the definitions involved, US sponsors must conduct an in-depth classification assessment of their ATMP. This initial assessment should evaluate the product against criteria from both FDA and EMA documents and should be documented exhaustively for future reference.

• Step 2.1: Gather Product Information – Essential details to consider include the type of biological material used, method of action, and intended patient population.
• Step 2.2: Characterize Product Features – Determine if the product acts primarily through gene therapy, somatic cell therapy, or tissue-engineered products. This step directly impacts classification.
• Step 2.3: Consult Existing Guidelines – Review guidelines provided by the FDA, EMA, and ICH to understand specific classification requirements applicable to your product. This can include examining related case studies and precedence.

Documenting the findings of this assessment creates a baseline for your classification risk register, highlighting the product’s unique characteristics and regulatory needs.

Step 3: Develop a Risk Register Document

With the foundational assessments complete, the next step is to develop the ATMP Classification Risk Register document. This comprehensive tool should do the following:

• Step 3.1: Outline Potential Risks – Using the classification assessments, identify potential risks associated with the product’s classification, including the likelihood of reclassification.
• Step 3.2: Include Regulatory Milestones – Map out important regulatory milestones applicable to both FDA and EMA pathways, clearly indicating dates by which actions need to be taken.
• Step 3.3: Formulate Compliance Actions – List actionable compliance steps that can be taken to mitigate identified risks, ensuring a proactive approach to maintaining classification.

Your risk register should be a living document, continually updated with new information and assessments as product development progresses and as feedback is received from regulatory interactions.

Step 4: Engaging in Regulatory Dialogue

Engaging with regulatory authorities early in the development process is crucial for US sponsors looking to minimize reclassification risks. Favorable interactions can ensure alignment on classification determinations and smooth subsequent regulatory submissions. This step can be broken down as follows:

• Step 4.1: Schedule Pre-IND Meetings with FDA – Before submitting an Investigational New Drug (IND) application, hold a meeting with the FDA to discuss product classification. Come prepared with your risk register and initial classification assessments.
• Step 4.2: Seek Scientific Advice from EMA – For products intended for the EU market, consider requesting scientific advice from the EMA to clarify classification issues early. This step ensures continuity of alignment across regulatory bodies.
• Step 4.3: Document Regulatory Feedback – All feedback received during these engagements should be documented thoroughly in the risk register, serving as a reference for future product development stages.

Maintaining clear communication with regulatory bodies not only minimizes reclassification risks but also builds trust, facilitating smoother pathways to market authorization.

Step 5: Iterative Reassessment of Product Classification

Regulatory pathways for ATMPs change dynamically as scientific understanding progresses, necessitating regular reassessment of product classification. This step involves:

• Step 5.1: Regular Schedule for Reassessments – Set periodic intervals (e.g., quarterly or semi-annually) for reassessing the product based on any new data, regulatory updates, or stakeholder feedback.
• Step 5.2: Update Risk Register Accordingly – Based on reassessments, document any amendments in the product classification, including any shifts from HCT/P 361 to 351 or similar changes.
• Step 5.3: Implementation of Feedback into Development Plans – Use the updated risk register to refine and enhance development strategies, ensuring that any emerging risks are addressed proactively.

This continuous cycle of assessment and documentation helps maintain awareness of regulatory expectations and can prevent late-stage surprises concerning product classifications.

Step 6: Preparing Submission Dossiers for Regulatory Agencies

Once the ATMP nears readiness for regulatory submission, specific documentation needs to be meticulously prepared. Both the FDA and EMA have defined expectations for submission dossiers regarding the development history, classification, and compliance with applicable regulations. This preparation consists of the following key steps:

• Step 6.1: Compile Essential Documentation – This includes a summary of manufacturing processes, preclinical and clinical data, all sections of the risk register, and correspondences with regulatory agencies.
• Step 6.2: Ensure Conformance with Regulatory Requirements – Cross-check the entire submission dossier against regulatory guidelines to ensure that it meets all required standards, especially concerning classification.
• Step 6.3: Distilling Data into Clear Formats – Use summary tables and clear charts to present data in an organized and easily interpretable manner to facilitate the review process by regulatory authorities.

A thorough submission dossier enhances clarity, minimizes delays during reviews, and reinforces the soundness of the product’s classification.

Step 7: Post-Approval Monitoring and Compliance Commitments

Post-approval, sponsors are obligated to maintain compliance monitoring to ensure adherence to the submitted classifications and any commitments made during the approval process. This includes:

• Step 7.1: Implement Post-Market Surveillance Plans – Develop and implement comprehensive post-market safety and efficacy monitoring plans that align with both FDA and EMA ongoing obligations.
• Step 7.2: Stay Updated on Regulatory Changes – Actively monitor streaming regulatory updates to adapt the risk register and compliance actions as necessary, especially in an industry known for rapid evolution.
• Step 7.3: Ongoing Regulatory Communication – Maintain an open channel of communication with regulatory bodies to report outcomes from your post-market practices and address any inquiries about the product classification.

This finalized approach to classification risk can safeguard the long-term viability of your ATMP while adhering to regulatory expectations.

Conclusion

Establishing a comprehensive ATMP Classification Risk Register is paramount for US sponsors looking to navigate the complexities of product classification effectively. By thoroughly understanding definitions, conducting assessments, engaging regulators, and maintaining ongoing vigilance, organizations can position themselves for compliance and successful market entry. Leveraging EMA ATMP regulatory consulting resources in conjunction with FDA guidance empowers sponsors to reduce the risk of late reclassification and streamline their development processes. By faithfully executing this roadmap, sponsors will not only facilitate their ATMP journey but also ensure they meet the rigorous demands of both national and international regulatory landscapes.